Against schizophrenia, Bitopertin, the first of a new class of medicines known as glycine reuptake inhibitors, has been proposed. Aim of Bitopertin, to treat the negative symptoms of schizophrenia, such as social withdrawal and lack of motivation. Approximately two-thirds of schizophrenia patients experience significant negative symptoms, and it has been suggested that a drug able to control them could become a blockbuster product. However the first two phase 3 trials on Bitopertin failed to meet the primary endpoint of a significant improvement on the positive and negative symptom scale (PANSS). By now, a third phase 3 study in patients with persistent negative symptoms is ongoing, with three more looking at the drug’s role in patients who continue to have positive symptoms despite antipsychotic therapy.